Innovent Biologics Lists on HKEX, Raises Over HK$3 Billion; WeDoctor Invests HK$200 Million to Build Greater Bay Area Collaborative Platform

In December 2018, the “2018 Top 100 Future Healthcare Forum,” themed “Trend ING,” jointly hosted by VCBeat, VBInsight, and the Future Healthcare Academy, is about to convene. To register, please click the link below or scan the QR code.

As one of the financial giants, no one doubts Ping An’s strength. Will the establishment of 1,000 third-party testing centers within five years usher in a new chapter for independent imaging centers?

What Changes Have Occurred in the Beauty Industry? Why Was the “New Beauty” Initiative Proposed at This Juncture, and How Is Meituan-Dianping’s Beauty Division Crafting a Model for the Future of the New Beauty Industry? VCBeat Provides an Analysis.

What is the strategic vision behind “One Store, One Window,” a joint initiative launched by Alibaba Cloud’s IoT Division and Ele.me? What disruptive potential does it hold for the new retail pharmaceutical sector? To explore these questions, VCBeat conducted in-depth interviews from multiple perspectives.

1. The pharmaceutical e-commerce industry will also see large-scale financing, boosting leading enterprises to expand their markets and go public;

2. Internet hospitals will become a standard feature for e-commerce platforms, with deployment through investment, self-construction, partnerships, and other models;

3. Integration of online and offline channels: e-commerce will expand into retail pharmacies, DTP (Direct-to-Patient) pharmacies, and other sectors;

4. Integration of B2B and B2C businesses, with the same enterprise engaging in multiple business lines;

5. Mergers and acquisitions will drive industry consolidation, with capital serving as the primary catalyst;

6. B2B e-commerce will become the sector with the greatest growth potential, entering a period of rapid development;

7. More new entrants are joining, bringing fresh gameplay and business models.

Pinduoduo Tests the Waters of E-Pharmacy

Recently, China Entrepreneur noted that an individual claiming to be a Pinduoduo employee was soliciting partnerships in various pharmaceutical e-commerce groups: “Friends in the pharmaceutical e-commerce community, I represent Pinduoduo in inviting enterprises with Internet Drug Transaction Certificates to join the Pinduoduo Medicine and Health Pavilion.” According to this employee, the so-called Pinduoduo “Medicine and Health Pavilion” refers to Pinduoduo’s Health Channel.

Alibaba’s New Retail Healthcare Unveils Fresh Strategy: ATM Model Aims to Build an Asset-Light Super Chain

On October 31, the unveiling ceremony for “Alibaba Empowers New Retail in Pharmaceuticals: ‘One Store, One Window’ Project” was held. The event showcased a 24-hour pharmacy operation model, ensuring that patients will no longer face difficulties purchasing medications in the middle of the night.

CDE Releases First Batch of List of Overseas New Drugs in Urgent Clinical Need, with Applications for Early Market Approval Available

To implement the spirit of the State Council’s executive meeting and accelerate the introduction of urgently needed overseas new drugs into China, the Center for Drug Evaluation (CDE) released the “Notice on Publishing the First Batch of Overseas New Drugs in Urgent Clinical Need” on its official website on November 1, selecting 48 such drugs.

Pharmaceutical Companies and Pharmacies, Take Note! These Matters Can Be Handled Immediately

On October 31, the Shanghai Municipal Drug Administration released an announcement on the catalog of approval service items subject to “immediate processing, online processing, local processing, and one-time processing.” Among these, services such as licensed pharmacist registration, approval for internet information services related to drugs and medical devices, and Good Supply Practice (GSP) certification for pharmaceutical products can now be handled directly online.

Innovent Biologics Lists on HKEX, Surging 19.2% in Intraday Trading

October 31 news: Innovent Biologics listed on the Hong Kong Stock Exchange today. The stock opened at HK$13.70 in yesterday’s grey market trading and closed at HK$14.10, representing a 0.86% increase over the offer price. It surged rapidly during trading, reaching HK$16.66 by midday, up 19.17%.

AstraZeneca Sells Two Gastric Drugs for $920 Million; Grünenthal Takes Over

On October 30, 2018, local time, the German pharmaceutical company Grünenthal announced its decision to acquire from AstraZeneca the commercialization rights for Nexium (esomeprazole) in the European market, as well as the global commercialization rights for Vimovo (naproxen/esomeprazole) in all regions except the United States and Japan, for $922 million.

This week, there were 18 financing events in the medical sector both domestically and internationally.

From an industry perspective, although the new asset management regulations are not sector-specific, institutions focused on early-stage investments in the healthcare and medical sector may be less affected. In previous years, certain industries were indeed overvalued; however, the healthcare sector is a weak-cyclical industry. Even amid uncertain economic prospects or downturns, people will still fall ill and require medical care—a certainty that remains unchanged.

DaoTong Investment primarily focuses on early-stage investments in the healthcare and medical industry, with a significant emphasis on healthcare services. We believe that the next three years present an excellent window of opportunity for healthcare services. (Source: PEdaily)

On October 30, The Hong Kong Polytechnic University announced the development of a robotic arm designed to assist stroke patients with limb rehabilitation training. This robotic arm is the first to integrate exoskeleton technology, soft robotics structural design, and the university’s proprietary peripheral nerve stimulation technology, offering advantages such as lightweight construction and rapid response. Preliminary trials have demonstrated that the device can improve patients’ muscle coordination, wrist and finger function, and the severity of muscle spasticity. The research team expects to commercialize this robotic arm within two years.

www.mobihealthnews.com

After nearly two decades of research and development, academic institutions such as the Kempenhaeghe Epilepsy Centre and Eindhoven University of Technology have launched NightWatch, a connected wristband. This product detects nocturnal seizures by monitoring heart rate and activity, and then alerts caregivers via wireless communication. A study published in the journal Neurology monitored 28 patients. Researchers found that this wearable device had higher accuracy than standard care sensors, detecting 85% of all seizures and 96% of tonic-clonic seizures. Moreover, healthcare professionals found the system easy to use, with an average user-friendliness score of 7.3.

www.mobihealthnews.com

10On the 30th, Interaxon announced the launch of Muse 2, a smart headband. Worn on the user’s forehead, it measures brain signals via EEG sensors and transmits the data to a corresponding mobile app to help the wearer enter a meditative state. What sets this product apart is its ability to track brain signals, heart rate, and breathing patterns during meditation, converting them into “soothing drumbeats” of varying sounds to facilitate meditation and help users gain insight into their inner state.

 www.mobihealthnews.com

In this article, we demonstrate how Parabricks, a high-performance NGS software suite based on NVIDIA graphics processing units (GPUs), accelerates computation, reducing the analysis time from two days to one hour and cutting costs to one-quarter of previous levels. Furthermore, we highlight its impact on leading genomics research centers such as BIOTEC, which plans to analyze thousands of samples annually. By shortening data analysis time from several days to just one hour, BIOTEC aims to achieve deeper insights that were previously unattainable.

This report provides a detailed exposition of the intentions and potential challenges faced by international biopharmaceutical companies in expanding into Asia, particularly the Chinese market. The research is primarily based on L.E.K.’s survey of international biopharmaceutical enterprises, industry data analysis, case studies of pharmaceutical companies, insights from industry experts, and the industry experience of L.E.K.’s Life Sciences practice. We hope this report will offer valuable insights for product in-licensing and business expansion within China’s biopharmaceutical industry.